Nature Reviews Cancer

Papers
(The H4-Index of Nature Reviews Cancer is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Computing brain metastasis impact1770
Digging for treasures in the tumour interactome1268
An inhospitable site668
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis623
Fructose takes a detour to feed cancer615
Implementing practice-changing progress for managing cancer of unknown primary412
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment411
Emerging strategies to investigate the biology of early cancer409
Oncofetal reprogramming in tumour development and progression407
INVADEseq to study the intratumoural microbiota at host single-cell resolution391
Exploiting metabolic cell death for cancer therapy356
Combinatorial strategies to target RAS-driven cancers354
How medical anthropology can contribute to cancer research347
Mapping the prostate cell family tree342
Fighting cancer with fat324
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’302
The recruitment of metastasis-associated monocytes283
Epithelial and stromal co-evolution and complicity in pancreatic cancer272
3D chromatin architecture as a predictor of somatic mutations in cancer genomes255
The evolution of cancer and ageing: a history of constraint236
Translating premalignant biology to accelerate non-small-cell lung cancer interception233
Context-dependent functions of pattern recognition receptors in cancer229
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel228
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma226
Gut microbes produce novel genotoxic metabolites221
Connie J. Eaves (1944–2024)221
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies221
Tertiary lymphoid structures as hubs of antitumour immunity221
No mutation, tumour initiation201
Nanoreceptors take down mutant p53201
Impersonating neurons199
Dendritic cells rise and shine198
Tumour EVPs disrupt liver function194
AACR 2025187
Measuring HLA disruption using MHC Hammer175
Persistence is key173
Thelpers? More like Ttroublemakers172
Remodelling of the tumour microenvironment by the kallikrein-related peptidases172
Removing barriers to address sex differences in anticancer drug toxicity165
Defining a ‘cells to society’ research framework for appendiceal tumours164
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer164
How chemokines organize the tumour microenvironment156
3D bioprinted cancer models: from basic biology to drug development155
Natural killer cells in antitumour adoptive cell immunotherapy150
Bone voyage: immune crosstalk sets sail145
B-ring sterols to the rescue142
Visualizing intratumoural heterogeneity with EpicMIBI140
Points of entry for tumour-infiltrating lymphocytes139
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer136
The immune microenvironment of colorectal cancer135
Identifying spatial cellular structures with SPACE-GM135
In-depth organoid profiling of pancreatic cancer133
Regulatory T cells in the tumour microenvironment127
Un-Fair Skin: racial disparities in acral melanoma research127
Metabolic interplays between the tumour and the host shape the tumour macroenvironment127
Leveraging the replication stress response to optimize cancer therapy126
The path to leptomeningeal metastasis123
Linking cell mechanical memory and cancer metastasis120
Dynamics and specificities of T cells in cancer immunotherapy115
In situ decellularization of tissues to resolve the tumour-associated matrix114
Understanding and addressing race disparities in childhood cancer outcomes108
Encoding spatial tumour dynamics with Starfysh107
Race influences the tumour microbiome106
Deciphering the cancer genome and epigenome101
The link between vitamin D and prostate cancer99
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic97
Polygenic scores in cancer96
Being in the zone89
ER stress sparks nerve pain89
Targeted protein degradation for cancer therapy88
Cancer nanomedicine87
Acetyl-CoA metabolism in cancer84
RNA splicing dysregulation and the hallmarks of cancer83
Z-nucleic acids give immunotherapy a boost81
Local CAR manufacturing79
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology78
Parity modulates epithelial–immune cell communication78
0.34621787071228